Clinical Trial Results:
A Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4 Therapy Versus High-Dose Interferon α-2b for Resected High-Risk Melanoma
Summary
|
|
EudraCT number |
2011-004257-29 |
Trial protocol |
IE Outside EU/EEA |
Global completion date |
|
Paediatric regulatory details
|
|
Is the trial part of an agreed EMA paediatric investigation plan? |
|
Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? |
|
Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? |
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
12 Mar 2025
|
First version publication date |
12 Mar 2025
|
Other versions |
|
Summary report(s) |
2011-004257-29 Results posted 24Feb2025 |
Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to Commission Guideline 2012/C 302/03
for further information.